Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28786664 | 0.90 | CPB2 (0.46) | CPB2 | |
| SCHEMBL30861186 | 0.85 | CPB2 (0.44) | CPB2 | |
| SCHEMBL30058897 | 0.85 | FOLH1 (0.42) | — | |
| SCHEMBL32665433 | 0.81 | C3AR1 (0.37) | CPB2 | |
| SCHEMBL31047745 | 0.81 | KMT2A (0.36) | — | |
| SCHEMBL18075699 | 0.79 | EPHX2 (0.35) | CPB2 | |
| SCHEMBL32665291 | 0.79 | ITGB1 (0.31) | ITGB1ITGA4 | |
| SCHEMBL18396446 | 0.77 | LMNA (0.50) | LMNA | |
| SCHEMBL32665115 | 0.77 | SMN1; SMN2 (0.33) | LMNAITGB1ITGA4 | |
| SCHEMBL32665213 | 0.72 | ITGB1 (0.32) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022143-A1 | Cyclic Peptide Inhibitors of IL-23 | JANSSEN PHARMACEUTICA NV (BE) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022143-A1 | Cyclic Peptide Inhibitors of IL-23 | IL23R, IL17A, IL36G | CPB2 1288/4885LMNA 1399/4885DPP7 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.